Who is sponsoring NCT01510145?

NCT01510145 is sponsored by Alcon Research.

What condition does NCT01510145 study?

NCT01510145 studies Open-angle Glaucoma, Ocular Hypertension.

What drugs are being tested in NCT01510145?

Interventions: Travoprost 0.004% BAK-free.

What is the status of NCT01510145?

NCT01510145 is currently COMPLETED.

Last reviewed 2014-05-15 · How we verify

Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN® BAK-free (0.004% Travoprost) in Patients Previously on Latanoprost Ophthalmic Solution 0.005% Monotherapy

NCT01510145 Phase 4 COMPLETED Results posted

The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® solution without BAK (benzalkonium chloride) after changing from prior latanoprost 0.005% ophthalmic solution monotherapy in subjects with open-angle glaucoma or ocular hypertension due to tolerability issues.

Details

Lead sponsor	Alcon Research
Phase	Phase 4
Status	COMPLETED
Enrolment	191
Start date	2012-02
Completion	2013-05

Conditions

Open-angle Glaucoma
Ocular Hypertension

Interventions

Travoprost 0.004% BAK-free

Primary outcomes

Change in Intraocular Pressure (IOP) at 12 Weeks From Prior Therapy (Baseline) — Baseline, Week 12
IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the efficacy analysis.